Farnesyltransferase inhibitors: targeting the molecular basis of cancer (Q33670187)

28 July 2017

1 reference

title

Farnesyltransferase inhibitors: targeting the molecular basis of cancer (English)

1 reference

28 July 2017

A Oliff

1

1 reference

PubMed ID

10382537

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

Biochimica et Biophysica Acta

28 July 2017

1 reference

28 July 2017

1423

1 reference

28 July 2017

3

1 reference

28 July 2017

C19-30

1 reference

Pharmaceutical research in molecular oncology

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Regulators and Effectors of ras Proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Function and regulation of ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

cDNA cloning and expression of the peptide-binding β subunit of rat p21rasfarnesyltransferase, the counterpart of yeast DPR1/RAM1

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Chaetomella acutiseta produces chaetomellic acids A and B which are reversible inhibitors of farnesyl-protein transferase.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Pseudopeptide inhibitors of Ras farnesyl-protein transferase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

NMR studies of novel inhibitors bound to farnesyl-protein transferase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Protein farnesyltransferase: structure and implications for substrate binding

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2899%2900007-4

7 January 2021

10.1016/S0304-419X(99)00007-4

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10382537